0 avis
Multidisciplinary analysis of cancer-related fatigue at the time of diagnosis: preliminary results of the BIOCARE FActory cohort
Archive ouverte
Edité par CCSD ; Springer Verlag (Germany) -
International audience. Purpose. Cancer-related fatigue (CRF) is a common side effect of cancer and cancer treatment that significantly impairs thequality of life and can persist for years after treatment completion. Although fatigue is often associated with cancer treatment,it is also a result of the disease itself, even before intervention. CRF at the time of diagnosis may affect treatmenttiming or completion and is a consistent predictor of post-treatment fatigue at any time. The mechanisms underlying CRFare multidimensional and not well understood, particularly at the time of diagnosis.Methods. Sixty-five breast cancer patients at the time of diagnosis were included. The participants completed self-assessmentquestionnaires about CRF, sleep disturbances, and emotional symptoms and wore an accelerometer to assess levelsof spontaneous physical activity and sleep quality. During the experimental session, the participants underwent cognitive,neuromuscular, and exercise metabolism evaluations.Results. Using augmented backward elimination regression, this study found that emotional symptoms and perceived sleepdisturbances were the strongest predictors of CRF (adjusted r2 = 0.51). Neuromuscular fatigability and sleep disturbancewere also associated with physical dimensions, whereas cognitive performance was associated with cognitive dimensions.Conclusion. At the time of diagnosis, emotional and cognitive dimensions are over-represented compared to the generalpopulation, and specific subdimensions have specific predictors that support the idea of distinct mechanisms. EvaluatingCRF subdimensions and their potential mechanisms at the time of diagnosis would be particularly relevant for identifyinghigh-risk patients and offering them appropriate interventions.Trial registration This study was registered at ClinicalTrials.gov (NCT04391543) in May, 2020.